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 Abstract
The Amaranthaceae family is composed of about 180 genera and 2500 species. These common weeds have become increasingly relevant 
as triggers of allergy in the last few years, as they are able to rapidly colonize salty and arid soils in extensive desert areas. The genera 
Chenopodium, Salsola, and Amaranthus are the major sources of pollinosis from the Amaranthaceae family in southern Europe, western 
United States, and semidesert areas of Saudi Arabia, Kuwait, and Iran. In Spain, Salsola kali is one of the most relevant causes of pollinosis, 
together with olive and grasses.
To date, 9 Amaranthaceae pollen allergens from Chenopodium album, Salsola kali, and Amaranthus retroflexus have been described and are 
listed in the International Union of Immunological Societies allergen nomenclature database. The major allergens of Amaranthaceae pollen 
belong to the pectin methylesterase, Ole e 1–like, and profilin panallergen families, whereas the minor allergens belong to the cobalamin-
independent methionine synthase and polcalcin panallergen families. These relevant allergens have been characterized physicochemically, 
and immunologically at different levels. Recombinant forms, allergenic fusion recombinant proteins, and hypoallergenic derivatives of these 
allergens have been expressed in bacteria and yeast and compared with their natural proteins from pollen. 
In this review, we provide an extensive overview of Amaranthaceae pollen allergens, focusing on their physicochemical, and immunological 
properties and on their clinical significance in allergic patients. We also review studies where these recombinant allergens and their 
hypoallergenic derivatives have been used in clinical diagnosis and their potential use in personalized therapy.
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 Resumen
La familia Amaranthaceae se compone de alrededor de 180 géneros y 2500 especies vegetales. En los últimos años, el polen de estas 
malezas está adquiriendo una relevancia cada vez mayor como inductor de alergia, ya que estas plantas son capaces de colonizar 
rápidamente los suelos salinos y áridos de zonas desertificadas.
El polen de los géneros Chenopodium, Salsola y Amaranthus es el causante del mayor número de casos de polinosis asociados a la familia 
Amaranthaceae en países del sur de Europa, oeste de Estados Unidos, y en las zonas semi-desérticas de Arabia Saudí, Kuwait o Irán. En 
España, el polen de Salsola kali es una de las causas más relevantes de polinosis junto con los pólenes de olivo y gramíneas. 
Hasta la fecha, se han descrito un total de nueve alérgenos del polen de Chenopodium album, Salsola kali y Amaranthus retroflexus, 
los cuales se han depositado en la base de datos de nomenclatura de alérgenos IUIS. Los alérgenos principales del polen de la familia 
Amaranthaceae pertenecen a las familias pectin metilesterasa, Ole e 1, o a la familia de panalérgenos -profilina-, mientras que los alérgenos 
secundarios descritos pertenecen a la familia de panálergenos -polcalcina-, o bien, corresponden a la metionina sintasa independiente 
de cobalamina. Estos relevantes alérgenos se han caracterizado fisicoquímica e inmunológicamente en mayor o menor profundidad. Las 
formas recombinantes, y sus variantes recombinantes o derivados hipoalergénicos fusionados a un tag, se han expresado en bacteria o 
levadura y se ha comparado su funcionalidad con sus correspondientes homólogos naturales presentes en el polen. 
En esta revisión, ofrecemos una extensa descripción de los alérgenos del polen de la familia Amaranthaceae, centrándonos en sus propiedades 
físico-químicas e inmunológicas, y en su importancia clínica en los pacientes alérgicos. Por otra parte, también hemos revisado aquellos 
estudios en donde se han utilizado estos alérgenos recombinantes y sus derivados hipoalergénicos en el diagnóstico clínico, o bien, en 
donde se describe su potencial uso en la terapia personalizada.
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1. Introduction
Weeds are difficult to classify in a specific botanical group 
or family. They are generally of little commercial or ornamental 
value and are known for their undesirable effect of invading 
cultivated environments and thus affecting the growth of other 
species [1]. Weeds are highly adaptive, especially in regions 
where the autochthonous vegetation has been damaged by 
drought and other adverse weather conditions. The high 
stability of weeds in unfavorable situations makes them 
major sources of pollens that cause allergic manifestations in 
increasing numbers of people [2-4].
The Amaranthaceae family has recently been extended to 
include the Chenopodiaceae family based on morphological 
and phylogenetic analyses [5]. Most of the members are annual 
and perennial plants whose growth is perfectly adapted to 
salty soils and arid environments, from which they draw high 
nitrogen concentrations. Although the family includes species 
of agricultural interest, such as Spinacia oleracea and the now 
popular Chenopodium quinoa and ornamental plants such as 
Amaranthus caudatus, a number of species are considered 
invasive [6,7]. The ability of these species to survive in 
hostile habitats does have advantages, namely, abundant seed 
production (often reaching 50 000 seeds per plant) and a 
fruit-dispersal mechanism that involves the whole plant (eg, 
tumbleweed). The tolerance of some species to toxic substances 
such as arsenic with no effect on growth contributes to their 
use as fixatives in highly polluted soils [8]. 
Members of the Amaranthaceae family share a number 
of morphological features in their pollen grains that make 
them indistinguishable using standard microscopy: the grains 
are spherical with a polypantoporate aperture arrangement 
that is similar to the surface of a golf ball [9-11]. Pollen 
production and release tend to be even lower than in other 
anemophilous species [12], thus reflecting optimal use of 
resources by xerophytic plants in adverse environments. 
Perhaps in an attempt to counteract this low pollen production, 
Amaranthaceae bloom from June to October [13], once the 
main pollination period of most species in temperate latitudes 
has finished [14].
Of all the species in the Amaranthaceae family, the genera 
Chenopodium, Salsola, and Amaranthus are the main triggers of 
summer allergy in countries with a temperate and dry climate, 
such as western United States and Australia and semidesert areas 
of Saudi Arabia, Kuwait, India, and Iran [15-18]. Desertification 
in extensive areas of the Mediterranean basin has increased 
the incidence of these weeds, causing symptoms in sensitized 
individuals, even at low concentrations [19-23]. The ability of 
Amaranthaceae weeds to resist drought, the ornamental use 
of several species in hedges and as irrigated crops, as well 
as their presence as contaminant weeds in cultivars at the 
expense of productive species such as olive tree, have increased 
their clinical relevance in the Mediterranean area. Since 
Mediterranean countries make up one of the world's largest 
surface areas of olive groves and olive pollen is the major local 
cause of allergy [24], an increase in polysensitizations to these 
pollen types is expected [25]. Different taxonomically related 
species of Amaranthaceae can induce allergic sensitization and 
could be used in diagnosis and treatment. 
From the allergological point of view, Salsola kali 
(also known as Russian thistle) and Chenopodium album 
(also known as lamb’s quarters) are considered the most 
representative pollens of the family in terms of incidence 
of allergy in Spain [26]. However, other species of the 
Amaranthaceae family, such as Salsola pestifer, Amaranthus 
retroflexus, and Salsola oppositifolia, have also been reported 
as allergenic species [27,28]. S kali is highly abundant in the 
southeast of Spain. Sepia vermiculata grows in swamps and 
marshy areas exposed to the sun, and Saxifraga oppositifolia 
can be found at roadsides near the sea in dry and hot areas. To 
date, the major allergens have been described and analyzed 
only in S kali, C album, and A retroflexus. A high degree of 
IgE cross-reactivity between allergens of the Amaranthaceae 
family has been reported since more than 2 decades ago [29].
The high number of allergenic molecules identified 
in these and other weed pollens (eg, ragweed, mugwort, 
pellitory, and annual mercury) are restricted to a few main 
families of proteins: enzymes, especially those involved in 
pectin metabolism (eg, pectate lyases, pectin methylesterases, 
and polygalacturonidases), defensin-like proteins, Ole e 1–
like proteins, the nonspecific lipid transfer proteins, and the 
panallergens profilin and polcalcin [3]. These families include 
the allergens detected in C album (Che a 1, Che a 2, and Che a 3), 
S kali (Sal k 1, Sal k 3, Sal k 4, and Sal k 5), and A retroflexus 
(Ama r 2) [17,30-48].
From a clinical perspective, and considering the dramatic 
rise in Amaranthaceae pollinosis in temperate countries, the 
qualitative and quantitative differences in allergenic content 
between extracts of various species, and the inaccurate 
diagnosis of patients due to the overlapping of allergenic 
weed pollens [28], Amaranthaceae pollens are expected to 
play an increasingly important role in the allergic response. 
Consequently, Amaranthaceae are expected to become 
one of the primary causes of pollen sensitization in the 
Mediterranean areas, as is the case in some areas of the Iberian 
Peninsula [23,49].
2. Allergens of the Amaranthaceae 
Family
Knowledge of the allergenic profile of a biological source 
is a prerequisite for improved diagnostic protocols and accurate 
immunotherapy. This knowledge is particularly important in 
the case of pollens, since the geographical distribution of plant 
species is strongly influenced by geophysical and climatic 
conditions. The use of purified allergens rather than currently 
available extracts has made it easier to identify the sensitizing 
allergen. The enormous efforts made in past decades to obtain 
the most significant allergens of the different pollen species 
have been essential for our understanding of the course to 
be followed by a given patient. Nine Amaranthaceae pollen 
allergens have been described to date (Table).
The Amaranthaceae family is composed of about 180 
genera and 2500 species. In Spain, these common weeds are 
increasingly relevant as triggers of allergy and are especially 
abundant in several regions of the southeast and the Ebro 
Valley. In the dry areas of the southeast (provinces of Alicante 
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and Murcia), levels of Amaranthaceae pollen range between 
100 and 250 grains/m3 from April to October, with a peak in 
August (www.polenes.com). Although these weeds release 
reduced numbers of pollen grains during the pollination season, 
around 40% of allergic individuals with symptoms at the end 
of summer are allergic to these aggressive pollens. In Spain, 
Salsola pollen, together with olive and grasses, is one of the 
main causes of pollinosis [26], both in regions where it is a 
major cause of sensitization (eg, Zaragoza and Murcia) and 
in regions where S kali grows wild in olive tree cultivars [50]. 
Salsola pollen has also been extensively associated with a 
high degree of IgE cross-reactivity between members of the 
Amaranthaceae family for decades [29]. 
In the Mediterranean area, the most relevant members of 
Amaranthaceae are S kali and C album [26,50]. Indeed, in 
southeastern and central areas of Spain, S kali pollen has been 
reported to produce pollinosis at almost the same level as olive 
and grass pollen [26,50,51]. 
2.1 Chenopodium 
Chenopod pollen is one of the best-characterized allergenic 
pollens of the Amaranthaceae family. Chenopod (C album) is a 
perennial plant. Although it can be found in all kinds of soils, it 
is mostly observed in arid and salt-rich soils [28,52]. Chenopod 
pollination takes place from June to October.
Areas of high clinical incidence have been reported in 
the south of Spain, western USA, Iran, Kuwait, and Saudi 
Arabia [22,26,28,44,52-55]. In countries with large areas 
of desert, such as Kuwait or Iran, chenopod pollens are the 
main sensitizing agents in patients with allergic rhinitis or 
asthma, and prevalence values are higher than those for 
dusts or molds owing to the use of this plant in greening 
programs [53-57]. 
Interestingly, polysensitization is usually observed in 
patients affected by chenopod pollinosis, and several authors 
have demonstrated pronounced cross-reactivity with related 
and nonrelated pollen extracts [29,58]. 
The 3 major allergens that have been described to date 
in C album pollen are Che a 1 (Ole e 1–like protein), Che 
a 2 (profilin), and Che a 3 (polcalcin) [36-38,44,53], which 
have been expressed in their recombinant form in yeast or 
bacteria [39,42,44,47,48,53] and were recently used for the 
diagnosis of C album allergy [44].
2.1.1 Che a 1
The first major allergen of chenopod pollen, Che a 1, 
was identified, characterized, and cloned in 2002 [37]. 
Using sera of olive- and chenopod-allergic patients and 
Ole e 1–specific rabbit antibodies, Barderas et al [37] 
identified an Ole e 1–like allergen of about 20 kDa using 
SDS-PAGE. Che a 1 was isolated from pollen and shown 
to be a glycoprotein of 17 088 Da and 143 amino acid 
residues in length. After cloning, its amino acid sequence 
exhibited 27%-45% identity with the sequences of several 
members of the Ole e 1–like protein family and only 30% 
identity with Ole e 1, thus explaining the limited cross-
reactivity between both molecules [37]. Remarkably, using 
a population of patients sensitized to chenopod and other 
pollens, the authors demonstrated that more than 70% had 
IgE against this molecule.
The same authors subsequently produced Che a 1 as a 
recombinant allergen in Pichia pastoris yeast [39]. Although 
the glycosylation pattern of recombinant Che a 1 differed 
from that of the natural protein, equivalent results were found 
for recognition of both natural and recombinant proteins 
by IgE [39]. More recently, expression of Che a 1 fused to 
a histidine tag has been reported in Escherichia coli [47]. 
Although the protein was isolated from inclusion bodies, 
on-column refolding of the recombinant protein enabled 
the authors to obtain a soluble protein able to bind IgE from 
Table 1. Allergens From the Amaranthaceae Family That Have Been Identified, Isolated, Characterized, and Expressed as Recombinant Proteins 
Species Allergen Accession Protein family Natural Source of Referencec 
  Numbera  Proteinb Recombinant Protein  
     Expression
Chenopodium album 
 Che a 1 Q8LGR0 Ole e 1–like [37] Pichia pastoris [39,47] 
 Che a 2 Q84V37 Profilin [36,38] Escherichia coli [30,40] 
 Che a 3 Q84V36 Polcalcin [36,38] Escherichia coli [42,48
Salsola kali 
 Sal k 1 Q17ST4, P83181  Pectin methylesterase [35] Escherichia coli [34] 
 Sal k 2 Q8L5K9 Protein kinase homologue  Not isolated Escherichia coli  
 Sal k 3 C1KEU0 Cobalamin-independent  Not isolated  Escherichia coli [33] 
   methionine synthase  
 Sal k 4 C6JWH0 Profilin [43] Escherichia coli [32,43] 
 Sal k 5 E2D0Z0 Ole e 1–like [41] Pichia pastoris [41
Amaranthus retroflexus 
 Ama r 2 C3W2Q7   Profilin Not isolated  Escherichia coli [46]
aAccession number as it appears in the UniProt database.
bReference for isolation of the natural allergenic protein from pollen.
cReference for expression of the allergen in a heterologous system.
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chenopod pollen–sensitized patients by either Western blotting 
or ELISA [47].
Unlike Ole e 1 and its recombinant form, the nonsignificant 
contribution of the glycan moiety to IgE recognition was shown 
in Che a 1 through the use of recombinant proteins expressed 
in both bacteria and yeast. The IgE binding properties of these 
proteins seem to be similar to those of nChe a 1 [39,47], in 
that the former does not contain any glycan and the latter has 
a different glycosylation pattern. 
2.1.2 Che a 2
In 2003, it was suggested that the panallergens Che a 2 
(profilin) and Che a 3 (polcalcin) played an important role 
in allergy to C album pollen [36]. This role was confirmed 
when the relevance of profilin and polcalcin in the allergenic 
properties of C album was also shown to be associated 
with polysensitization in chenopod pollen–sensitized 
patients [36,38].
In 2004, both panallergens were further studied using 
104 sera from individuals with C album allergy [38]. Natural 
Che a 2 was purified to homogeneity from C album pollen 
extract and used to investigate the relevance of profilin in 
chenopod allergy. Indeed, C album profilin was reported to 
be a major allergen in C album allergy, since 55% of the 104 
sera tested showed positive IgE responses by ELISA [38]. A 
similar finding was observed in 2011 by Nouri et al [44], who 
showed that Che a 2 was a major allergen.
Barderas et al [38] reported the cDNA-encoding sequence 
of Che a 2 and investigated its amino acid sequence identity 
with other allergenic profilins deposited in databases. The 
3 cDNA clones coding for Che a 2 ranged between 131 and 
133 amino acids in length for a molecular mass of about 
14 kDa and an acidic isoelectric point (pI) of about 5 [38]. 
Remarkably, Che a 2 showed higher amino acid sequence 
identity with Hev b 8 (the profilin from latex) and plant-
derived food profilins (Mal d 4 [apple] or Ara h 5 [peanut]) 
than with pollen profilins (Ole e 2 [olive], Bet v 2 [birch], 
and Phl p 12 [grass]) [38]. 
Later in the same year, the heterologous expression of 
Che a 2 as a nonfusion protein was reported in E coli [40]. 
Recombinant Che a 2 was produced as a soluble protein, purified 
to homogeneity, and characterized in detail using antiprofilin 
polyclonal antiserum and sera from C album–pollen allergic 
patients. rChe a 2 showed similar immunological properties to 
those of the natural allergen isolated from pollen, as determined 
by immunoblotting, ELISA, and inhibition experiments [40].
The cross-reactivity of Che a 2 was investigated in detail 
using ELISA inhibition experiments with the recombinant 
form and inhibitors (pollens, plant-derived foods, and latex 
extracts) [40]. Inhibition levels higher than 80% were reported 
with pollen and latex allergens and between 10% and 95% with 
plant-derived food extracts, thus further demonstrating the 
importance of Che a 2 in cross-reactivity [36,38,40].
2.1.3 Che a 3
The third panallergen from C album pollen is the 
polcalcin Che a 3 [36,38]. In the report by Barderas et al [38], 
Che a 3, which is a 2-EF-hand calcium-binding protein, was 
also addressed in detail. Che a 3 was isolated from pollen 
and shown to react with 46% of 104 C album–sensitized 
patients by ELISA [38]. Interestingly, similar recognition 
of IgE binding (41%) was observed in Iranian sensitized 
patients [44]. 
The cDNA-encoding sequence of Che a 3 was reported 
by Barderas et al [38] in 2004, and its amino acid sequence 
identity was compared to that of other reported polcalcins. 
The Che a 3 cDNA clone was 86 amino acids in length for a 
theoretical molecular mass of 9.5 kDa and a pI of 4.43 [38]. 
Remarkably, Che a 3 had an amino acid sequence similarity 
of up to 90% with Bet v 4 (birch polcalcin), and 89% with 
Ole e 3 and Aln g 4, polcalcins from olive and alder pollen, 
respectively, thus indicating the highly potent cross-reactivity 
of Che a 3 with other polcalcins [36,38]. 
The ability of Che a 3 to cross-react was investigated in 
detail using its recombinant form produced as a nonfusion 
protein in E coli [42,48]. After purification to homogeneity, 
Che a 3 was able to inhibit up to 50% of IgE binding to grass 
pollen polcalcin (Phl p 7), while Phl p 7 inhibited 76% of the 
IgE binding to immobilized Che a 3 [42]. The 3D structure 
of Che a 3 was solved by x-ray crystallography [48]. The 
comparison of the Che a 3 structure with that of polcalcin 
allergens from grass pollen (Phl p 7) and birch pollen (Bet 
v 4) showed that all 3 allergens displayed almost equivalent 
folding but different oligomeric behavior [48]. Che a 3 and 
Phl p 7 are structured as dimers, while Bet v 4 is found mainly 
as a monomer [48].
2.2 Salsola
Salsola is the genus from the Amaranthaceae family 
whose allergenic properties have been best characterized. 
Salsola comprises several allergenic species, including S kali, 
S pestifer, S vermiculata, and Salsola soda [16,59-62]. 
The only species whose allergens have been identified is 
S kali [31-35,41,43, 59]. The other allergenic species have 
barely been characterized using immunochemical assays, and 
their IgE-reactive bands are grouped according to molecular 
mass. As with most Amaranthaceae weeds, S kali is a typical 
plant of salty soils and is found mainly in dry habitats [63]. 
S kali is a summer-flowering, annual weed, which matures to 
form spherical bushes (tumbleweeds). 
The first cases of sensitization to S kali pollen were reported 
in Arizona, USA [64]. Since then, multiple sensitizations have 
been described worldwide, as the plant is found extensively in 
dry soils. In the USA, S kali can be found from the northeast 
to the west, and in Europe, from the Baltic coast to the 
Mediterranean coast. It is also observed in North Africa and 
some Arab countries [26,52]. In Spain, S kali is very common 
in Aragón, Andalucía, Murcia, Levante, and Zaragoza (the 
area with the second highest sensitization rate) [65]. Indeed, 
in some southeastern and central areas of Spain, sensitization 
to S kali is almost as frequent as sensitization to olive and 
grass [26,50,51]. In addition, S kali constitutes the main cause 
of pollinosis in Iran [60].
Extensive cross-reactivity has been reported between 
S kali pollen and Amaranthaceae pollens and other, nonrelated 
pollen extracts [29,58]. Interestingly, in contrast with 
C album–sensitized patients, most of whom are polysensitized, 
monosensitization to S kali is common [65].
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Figure 1. Allergogram of Salsola kali pollen protein extract. A, Protein profile of the S kali pollen extract after 2D electrophoresis and staining with silver. 
B, IgE reactive bands using sera from S kali pollen–sensitized patients. IgE-reactive spots corresponding to Sal k 1, Sal k 4, and Sal k 5 can be identified 
in the figure. C, 3D modeling of the allergens Sal k 1, Sal k 2, Sal k 3, and Sal k 4 from S kali pollen. The amino acid sequences of these allergens are 
deposited in the protein data bank and are homologous with previously defined 3D structures. The models were obtained from the Swiss PdbViewer and 
visualized with PV-JavaScript Protein Viewer. pI indicates isoelectric point.
The allergens present in S kali pollen have been 
studied extensively in recent years. Despite the complex 
allergogram of the pollen protein extract (Figure 1), only 
5 allergens have been identified and characterized to 
date, and 4 have been produced as recombinant proteins 
[31-35,41,43].
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2.2.1 Sal k 1
Sal k 1 was the first allergen identified from S kali [35,59]. 
It is a very polymorphic protein with a molecular mass of 
around 37 kDa and more than 20 isoforms with isoelectric 
points ranging from pI 4 to 9.5. Sal k 1 belongs to the pectin 
methylesterase protein family [35,59] and can be considered a 
major allergen, since more than 50% of sensitized patients are 
allergic to it [34,35,59]. Sal k 1 is responsible for up to 80% of 
cases of sensitization to S kali. Indeed, Sal k 1 was proposed as 
the marker of sensitization to S kali pollen, since it was shown 
to be the main reason for the differences in sensitization to 
S kali and C album pollen [35].
Expression of Sal k 1 in E coli was reported in 2010 [34]. 
The recombinant protein was produced as a soluble protein 
tagged with thioredoxin to increase the solubility of 
recombinant fusion and with histidine to ease purification [34]. 
Immunoblotting, ELISA, and inhibition experiments using 
sera from S kali–sensitized patients showed that the fusion 
protein was able to bind specific IgE to the same extent as 
the natural molecule isolated from pollen [34]. In the same 
report, the authors described a low IgE-binding variant of 
Sal k 1 modified by mutation of predicted B-cell epitopes and 
produced using the same approach [34]. Indeed, the rSal k 1 
mutant exhibited reduced IgE-binding capacity against the 
wild-type rSal k 1 both in vitro and in vivo. Accordingly, the 
authors suggested using this molecule for immunotherapy. 
Barderas et al [35], who first cloned the major allergen of S kali 
pollen, recently produced Sal k 1 in bacteria and yeast (personal 
communication) and demonstrated the scant involvement of 
the glycan moiety in sensitization to Sal k 1. The authors 
also demonstrated the potential use of recombinant Sal k 1 
in clinical diagnosis, since it spans all the immunological 
properties of the most representative isoforms in the natural 
pollen protein.
2.2.2 Sal k 2
The nucleotide sequence of Sal k 2 was deposited in 
the EMBL/GenBank/DDBJ databases (accession number: 
Q8L5K9) in 2002. Sal k 2 was identified as a protein kinase 
homologue because of its conserved catalytic core. The protein 
is composed of 320 amino acids and has a molecular mass of 
about 36 kDa. However, other than the reported sequence, 
no additional data on Sal k 2 or its allergenic relevance are 
available.
2.2.3 Sal k 3
Sal k 3 was first identified in 2011 by Assarehzadegan et 
al [33] through fractionation of S kali pollen extract by SDS-
PAGE and IgE-immunoblotting. The authors confirmed the 
identification using mass spectrometry. The 45-kDa protein 
was identified as a fragment of a cobalamin-independent 
methionine synthase of about 85 kDa [33]. The authors 
produced the recombinant allergen in the 2 fragments of 
the wild-type protein according to the fragment of the 85-
kDa protein in the 45- and 40-kDa protein subunits. The 
recombinant proteins were fused first to a thioredoxin tag 
and then to a histidine tag [33]. After extensive purification 
of the recombinant protein, Sal k 3 was characterized by IgE-
immunoblotting, inhibition assays, and skin prick tests. Both 
fragments of Sal k 3 possessed IgE-binding ability and were 
able to inhibit the natural protein of the pollen extract [33]. 
2.2.4 Sal k 4
Sal k 4, the profilin from S kali pollen was first characterized 
in 2010 by Arilla et al [32], who cloned 2 different isoforms 
of Sal k 4 and expressed 1 of them fused to thioredoxin and 
histidine tags. The authors also showed the high IgE cross-
reactivity of S kali profilin with other profilins from chenopod 
and olive pollen [32].
A new report on S kali profilins published in 2011 [43] 
revealed the presence of a low IgE-binding profilin isoform 
among isoforms identified by 2D electrophoresis. Two different 
isoforms were cloned and expressed as nonfusion proteins in 
bacteria. Modeling the 3D structure of both isoforms and their 
different IgE-binding ability (which suggested a hypoallergenic 
character for 1 of them) and the findings of previous epitope 
mapping studies enabled the authors to propose the amino 
acid residues involved in the loss of IgE-binding ability. Of 
particular interest, the authors produced a hypoallergenic 
derivative identified from S kali pollen, which might be a 
good candidate for desensitization protocols using cocktails 
of recombinant allergens [43], as in the clinical diagnosis of 
sensitization to C album pollen [44,53].
2.2.5 Sal k 5
In 2009, an Ole e 1–like protein, Sal k 5, was detected in the 
pollen of S kali. Moreover, a high level of IgE cross-reactivity was 
detected between Sal k 5 and its homologue in C album pollen, 
Che a 1, although cross-reactivity with Ole e 1 was very low.
Data on the identification and characterization of Sal k 5 
were reported by Castro et al [41] at the end of 2013, when 
the authors also published their report on the recombinant 
expression of the protein in P pastoris yeast. The purified pollen 
allergen was a glycoprotein measuring 151 amino acid residues 
in length for a molecular mass of about 17 kDa. Its amino acid 
sequence exhibits 68% and 32% identity with Che a 1 and 
Ole e 1, respectively. The frequency of sensitization to Sal k 5 
was between 30% and 40% based on 2 different populations 
of S kali–sensitized patients in the center and on the east coast 
of Spain [41]. Moreover, the recombinant protein was shown 
to behave similarly to the natural pollen protein in terms of its 
physicochemical, and immunological properties [41]. 
2.3 Amaranthus
The genus Amaranthus is found worldwide as short-lived 
perennial plants. Amaranthus comprises about 60 species with 
inflorescences and foliage ranging in color from purple and 
red to green and gold. 
Amaranthus mainly contains weeds, some of which are 
used as ornamental plants. Others are highly valued as leaf 
vegetables or cereals. There are several reports on the allergenic 
potential of Amaranthus pollen [27,29,58,65,66], and the 
amaranth grain (Amaranthus paniculatus) has been reported 
to produce food allergy [67].
The pollen of A retroflexus, Amaranthus viridis, and 
Amaranthus spinosis has been described as allergenic [27,66], 
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although the only pollen characterized through identification 
of allergenic proteins is A retroflexus [46]. In fact, this weed is 
a major trigger of allergic reactions in Iran, where about 69% 
of allergic patients are sensitized. Cross-reactivity with several 
species of the Amaranthaceae family has been widely confirmed 
using different immunological techniques [22,27,29,58,65].
2.3.1 Ama r 2
The protein profile of crude A retroflexus extract showed at 
least 9 IgE-reactive bands ranging from 10 kDa to 70 kDa, with 
main bands at 10, 15, 18, 25, 39, 45, 50, 66, and 85 kDa [46].
The profilin Ama r 2, which is the only allergen of 
A retroflexus pollen detected to date, was first reported in 
2011 [46]. Ama r 2 was detected by immunoblotting and its 
sequence was cloned and then expressed as a soluble His-
tagged protein in E coli [46]. Four of 12 A retroflexus–sensitized 
patients (33%) had sIgE against Ama r 2 [46]. The authors also 
showed that recombinant Ama r 2 was able to induce a wheal in 
skin prick testing, thus confirming its allergenic potential [46]. 
Finally, high cross-reactivity of Ama r 2 with profilins from 
other Amaranthaceae species—S kali (Sal k 4) and C album 
(Che a 2)—has been reported [46].
3. Recombinant Allergenic Derivatives 
for Diagnosis and Therapy of 
Amaranthaceae Allergy
IgE-mediated diseases are currently one of the most 
common health problems worldwide. About 25% of the world’s 
population has some type of allergy [68-70], and children are 
the most affected segment of the population [70,71]. In recent 
decades, prevalence has increased and is notably higher in 
developed countries [72].
Amaranthaceae pollen has become one of the most 
common allergic triggers because climatic and environmental 
changes have produced extensive desert areas that are rapidly 
colonized by this family [19-23,26,50,51], thus increasing the 
risk of sensitization to Amaranthaceae pollen.
Rapid and effective diagnosis of the different sources to 
which a patient is sensitized is essential if we are to reduce 
exposure to allergenic molecules, symptoms of allergy, 
and visits to the emergency department because of allergic 
reactions. We will also be in a better position to evaluate 
prognosis. Triggering of allergy symptoms can be avoided with 
drugs such as corticosteroids, antihistamines, and epinephrine. 
Other drugs that can be administered to relieve symptoms 
after onset include anticholinergics and decongestants. 
However, these drugs are palliative. The only currently 
available treatment that modulates the course of the disease 
and has a long-lasting therapeutic effect is specific allergen 
immunotherapy (SIT) [73,74], which consists of subcutaneous 
or sublingual administration of increasing doses of crude 
extracts of the natural source until the patient is able to tolerate 
the allergen. Treatment lasts 2 or 3 years or even longer [75].
Biological extracts contain several allergens and 
nonallergenic molecules. The amounts of the most relevant 
allergens vary depending on the source material, and major 
variations in the quality of allergenic extract batches have 
been observed [76]. Natural extracts are also affected by the 
low levels of specific allergen components and contamination 
with other allergens or bacterial components. The advent of 
recombinant allergens has resolved these issues [77].
During the last 3 decades, hundreds of allergenic 
molecules have been identified and characterized in depth, 
and many have been produced as recombinant proteins 
(Figure 2). Recombinant production of allergens makes it 
possible to obtain high amounts of protein, thus facilitating 
characterization of the molecule and application in clinical 
practice. In most studies, in-depth physical, chemical, 
and immunological characterization of allergens has been 
performed to assess the quality of the recombinant protein 
and determine its allergenicity [78], thus making it possible 
to distinguish between relevant allergens and those with 
IgE-binding ability but minor clinical significance [79-81]. 
Moreover, the comparison of the recombinant allergen with its 
natural counterpart has facilitated investigation not only of the 
properties that make a molecule an allergen, but also the use of 
allergens in the clinical diagnosis of allergy (eg, component-
resolved diagnosis and microarray-based diagnosis) [79-84].
Clinical diagnosis by identification of the components of 
an allergen to which a patient is sensitized using natural or 
validated recombinant allergens can optimize desensitization 
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Figure 2. Design and production of recombinant allergenic derivatives 
with allergenic properties (naïve or altered) and potential use in clinics 
for diagnosis and therapy of allergic diseases.
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protocols based on SIT [79-84]. In this sense, component-
resolved diagnosis has become essential in patients whose 
routine diagnosis is unclear and who therefore cannot receive 
successful treatment [79-84]. As for Amaranthaceae allergy, 
Sal k 1 is the only allergen used to date in component-resolved 
diagnosis by ImmunoCap (Phadia), since it is the sensitization 
marker of S kali pollen. However, its inclusion in component-
resolved diagnosis based on Che a 1 or Sal k 5, both of which are 
markers of Amaranthaceae allergy, will enable firmer diagnoses.
The large body of knowledge on validated recombinant 
allergens has facilitated the design of molecules with 
altered allergenic properties. Hypoallergenic derivatives or 
peptides used instead of unmodified allergens have been 
boosted to overcome the risk of adverse reactions during 
desensitization [80]. These derivatives have been proposed 
as a means of improving SIT by ensuring shorter regimens 
and enhanced safety profiles. In recent years, several reports 
have demonstrated the feasibility of these molecules as a 
replacement for whole allergen extracts in SIT [81-85]. 
In addition, studies reporting data from clinical trials have 
demonstrated the feasibility and safety of recombinant allergens 
and hypoallergenic variants for desensitization by SIT [81,85-90]. 
In this sense, 2 recombinant allergenic derivatives used as vaccines 
can induce allergen-specific IgG while reducing allergen-specific 
IgE in sensitized patients [81,85].
Recombinant hypoallergenic derivatives of Amaranthaceae 
have also been produced [43,45], and a cocktail of recombinant 
allergens has proven safe and more accurate for the clinical 
diagnosis of C album sensitization by skin prick test [44,53]. 
Furthermore, a fusion-based hypoallergenic derivative 
composed of 3 recombinant allergens (Che a 1, Che a 2, and 
Che a 3) is now being tested in clinical trials for specific 
desensitization in patients who are allergic to C album [45]. 
This fusion protein was expressed in bacteria as a soluble His-
tagged protein. The recombinant trimeric allergenic molecule 
was shown to have reduced IgE-binding properties (probably 
as a consequence of secondary structural alterations) compared 
with effectiveness of the mixture of the 3 independent 
recombinant allergens, whose low tendency to aggregate 
and preserved T-cell activation properties led the authors to 
consider it a candidate for immunotherapy in patients allergic 
to C album [45].
Remarkably, more and more hypoallergenic derivatives are 
now ready for preclinical and clinical studies, indicating that 
in the near future, both clinical diagnosis of components and 
personalized immunotherapy could be based on recombinant 
allergens.
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CME Items
1. Which of the following allergenic species do not 
belong to the Amaranthaceae family?
a. Salsola kali
b. Chenopodium album
c. Amaranthus retroflexus
d. Olea europaea
2. What is the main reason for the increasing 
prevalence of sensitization to Salsola kali in Spain?
a. High levels of pollen 
b. Adaptation to humid environments
c. Pollination throughout year
d. Desertification due to climate change
3. At what level is Salsola kali pollen sensitization in 
Spain?
a. Higher than the olive sensitization level
b. Higher than the grass sensitization level
c. At the same level as grass sensitization
d. Lower than the grass and olive sensitization levels
4. How many allergens have been characterized to date 
in Amaranthaceae pollen?
a. 5
b. 7
c. 9
d. 15
5. Which family of Amaranthaceae allergens accounts 
for the highest prevalence value reported to date?
a. Pectin methylesterase
b. Ole e 1–like
c. Profilin
d. Polcalcin
6. Which allergen has been used to obtain a 
hypoallergenic derivative for desensitization 
protocols?
a. Che a 1
b. Che a 2
c. Che a 3
d. All of the above
7. What are the usual characteristics of Amaranthaceae 
pollen–sensitized patients?
a. Monosensitization to Salsola kali
b. Polysensitization to Chenopodium album and 
other pollens
c. Monosensitization to Chenopodium album
d. Both a and b are correct
8. Which allergen family is shared by Salsola kali and 
olive pollen?
a. Pectin methylesterase
b. Ole e 1–like allergens
c. Profilin
d. All of the above are correct
9. Of which of the following protein families is Sal k 4 
a member?
a. Polcalcin
b. Pectate lyase
c. Profilin
d. Pectin methylesterase
10. Which of the following families has been described 
as allergenic in all Amaranthaceae pollens?
a. Pectin methylesterase
b. Ole e 1–like
c. Profilin
d. Polcalcin
